Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Pediatric Rheumatology
What additional immunomodulation would you consider in a patient with severe NXP-2+ JDM who has already received cyclophosphamide and rituximab but has persistent gastrointestinal vasculopathy?
Answer from: at Academic Institution
I'd try a JAKi.
Sign in or Register to read more
19547
Related Questions
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
What is your approach to practical monitoring of lupus disease activity in clinical practice?
Do you recommend starting aspirin for a patient with ESKD secondary to lupus nephritis with detected antiphospholipid antibodies on pretransplant workup but no history of a thrombotic event?
How will you approach tapering sarilumab in patients with PMR in remission?
Have you seen drug induced SCLE from IL-17 inhibitors?
What is your approach to managing osteoporosis in patients with end stage kidney disease?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
In patients with history of anaphylaxis to a TNF inhibitor, are you comfortable trying an alternative TNF inhibitor?
How do you make the decision to empirically treat for GCA when a patient is referred but cannot be immediately seen in clinic?
What is your approach to pharmacologic treatment options in a patient with both SLE and Crohn's disease?